 |
|
Tadalafil-Induced Subretinal and Choroidal Hemorrhage in a Patient With an Unsuspected Uveal (Choroidal and Ciliary Body) Melanoma
David H. Abramson, MD;
Indira S. Rollins, RN;
Amy Lin, MD;
Peter Odell, MD;
Robert Folberg, MD
Arch Ophthalmol. 2006;124:1058-1060.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Tadalafil (Cialis; Lilly ICOS LLC, Bothell, Wash) is a Food and Drug Administration–approved phosphodiesterase type 5 (PDE5) enzyme inhibitor approved for the treatment of erectile dysfunction. Although preclinical testing of tadalafil and sildenafil citrate (Viagra; Pfizer Inc, New York, NY) included an extended eye examination, electroretinography, and postmortem histologic analysis and no adverse effects were seen, a variety of studies have subsequently highlighted ophthalmic problems with both agents. Transient changes in vision, transient and mild impairment in color discrimination, eye pain, eyelid swelling, electroretinographic abnormalities,1-3 abnormal histopathologic findings,4 pupil-sparing third nerve palsy,5 and central serous choroidopathy have been reported.6
We recently observed a male patient who suddenly developed a painful red eye and loss of vision after taking tadalafil and was found to have ruptured blood vessels in and on the surface of . . . [Full Text of this Article] Report of a Case
Comment
AUTHOR INFORMATION
|
